Alone or in combination w/ HMG-CoA reductase inhibitor (statin) as adjunctive therapy to diet for reduction of elevated total cholesterol (total-C), LDL-C, Apo B, triglycerides & non-HDL-C, & to increase HDL-C in adult & adolescent 10-17 yr w/ primary heterozygous familial & non-familial hypercholesterolemia. In combination w/ fenofibrate as adjunctive therapy to diet for reduction of elevated total-C, LDL-C, Apo B & non-HDL-C in adults w/ mixed hyperlipidemia. Administered w/ statin to reduce risk of CV events (CV death, non-fatal MI & stroke, unstable angina hospitalization, or need for revascularization) in patients w/ CHD; for reduction of elevated total-C & LDL-C levels in adult & adolescent 10-17 yr w/ HoFH. Administered w/ simvastatin to reduce risk of major CV events in patients w/ CKD. Adjunct to diet for reduction of elevated sitosterol & campesterol levels in patients w/ homozygous familial sitosterolemia.
Sign Out
